Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD - sprookjes - yvandenbroek - TriplyDB

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

http://www.wikidata.org/entity/Q28188441

about

Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma Positron emission tomography (PET)-adapted therapy for Hodgkin lymphoma patients Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors Health-related quality of life in Hodgkin lymphoma: a systematic review Immunotoxin - a new treatment option in patients with relapsed and refractory Hodgkin lymphoma ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial EBVD combination chemotherapy plus low dose involved field radiation is a highly effective treatment modality for early stage Hodgkin's disease Hodgkin lymphoma, version 2.2015.Advance and stagnation in the treatment of patients with lymphoma and myeloma: Analysis using population-based cancer registry data in Japan from 1993 to 2006.Systems of protocol review, quality assurance, and data audit.Bystander cells and prognosis in Hodgkin lymphoma. Review based on a doctoral thesis.Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma.Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation ABVE-PC and modified BEACOPP regimen in Indian children with Hodgkin lymphoma: Feasibility and efficacy Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.Role of chemotherapy in Hodgkin's lymphoma.Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis Disparities in survival after Hodgkin lymphoma: a population-based study Evidence-based management of Hodgkin's disease: the role of autologous stem cell transplantation.Historical review of lymphomas.Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.Adverse events associated with chemotherapy for common cancers.Treatment strategies for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH).Role of Radiotherapy in Modern Treatment of Hodgkin's Lymphoma Hodgkin's lymphoma therapy: past, present, and future.Recent developments in the management of haemophagocytic lymphohistiocytosis.Incidence patterns and outcomes for hodgkin lymphoma patients in the United States Should involved-field radiation therapy be used as an adjunct to lymphoma autotransplantation?Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites.A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly).Approach to Hodgkin's lymphoma in the new millennium.Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management.MiR-SNPs as markers of toxicity and clinical outcome in Hodgkin lymphoma patients The emergence of resistance to targeted cancer therapeutics.T-cell rich B-cell lymphoma: clinical distinctiveness and response to treatment in 45 patients.Clinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential.

P2860

Q24186668-F24213E4-5945-4806-AC6E-95F8FD7354F6 Q24202622-378E0673-C909-47C5-9B83-44112892F2A8 Q24234975-59BEDDD6-CE1A-4845-B31C-C5C1A5ECF120 Q24240697-8913966D-A6BD-4403-884E-0CD0372BDA3C Q24683022-91711C84-EBED-4C32-8ABF-8C38AD3C5FA0 Q26740480-77FCEE0A-A37F-41B9-902B-1D5C06A45AC9 Q26772848-FA49AD70-BEB1-4C2F-97E7-44C381CC2819 Q28365255-487B6D37-9BD7-4DC8-83D1-EFEE57C31A24 Q28373416-BFC343F6-081E-45E7-B1B5-2E062863E05C Q30769157-57E5FE27-617F-4A7F-83E4-E16E8F22DB4B Q30895580-1960A7CA-41E1-4A19-80F8-37AD12601D60 Q32016096-0007F7D8-5E51-4AFA-965C-8EDF2A7075FB Q33208378-9759BA4F-7C0A-4715-ABB9-AE6B82AC6E49 Q33365711-890203B6-D627-4B3D-A42B-1DF824F6EC54 Q33373091-FCE903C5-EB7F-4E27-A39C-E87E901095BD Q33400803-222EC60D-C5BD-4BBF-8A64-5CE3F31090E1 Q33432165-1805B5EE-C09A-43FB-8FAD-742A5CA9F60D Q33442092-EB6C643B-AD7C-4E6B-9785-2C7694CF3A47 Q33761103-70AA7409-F23D-495C-B261-F4C4C12FB436 Q33886243-B21E426D-F1AD-4FC4-A6F5-DB0B993AEA40 Q33925220-B08420B0-F8DC-47C3-AEEE-4D9929BB309C Q33930383-CF3E23FD-C590-464B-A80E-FACDD6DAD98D Q33962044-CF64E6F4-8A31-4EC7-A3A5-91864C2931C7 Q33962334-2A00A42A-4024-47AF-BE6B-D40A6DB96128 Q33975228-22474561-46D6-4A66-8060-2C1829FFBB0D Q34024242-C8328891-17A4-44FA-A096-14F825A760BA Q34235785-EEB29B1D-E011-4271-8186-4B0FCFCBF7EF Q34296914-1861EEAE-5D8E-4838-A327-5656DCAA344D Q34390355-D14B45B3-CA5B-47A5-8833-1DB35B898805 Q34442533-870C2244-2F14-4D62-971B-AC8FF307EDF7 Q34541079-46CEEC10-EBDB-4356-A2D8-0257CB3BE9C4 Q34548300-58B7B9D0-A352-4299-9C68-68C13BF78EE6 Q34553446-4A15BE30-0A30-4591-B123-E62E977C4198 Q34580600-FAF2A4E2-C8B5-4F94-A0B8-33048F0512FF Q34645722-719C6DD2-62E1-4B60-85F5-AEF47E5CBB1B Q34662648-36BBCD6E-D4FB-4A80-82B9-0CA9C315D0A3 Q34738140-8F1E38D9-C0F8-410E-B04D-303ECCB75D75 Q34837015-1B1BBBFE-1187-4B4E-98E0-E0F20BD9C131 Q34980364-64A427B8-A9DF-4AAC-8E8C-B42EC7DE534F Q35021459-194F84F1-334C-4A35-8EE6-B55E6A0E5073

P2860

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

http://www.wikidata.org/entity/Q28188441

description

1992 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

1992 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

artículu científicu espublizáu en 1992

@ast

im November 1992 veröffentlichter wissenschaftlicher Artikel

@de

scientific article (publication date: 19 November 1992)

@en

vedecký článok (publikovaný 1992/11/19)

@sk

vědecký článek publikovaný v roce 1992

@cs

wetenschappelijk artikel (gepubliceerd op 1992/11/19)

@nl

наукова стаття, опублікована в листопаді 1992

@uk

مقالة علمية (نشرت في 19-11-1992)

@ar

name

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

@ast

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

@en

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

@nl

type

label

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

@ast

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

@en

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

@nl

prefLabel

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

@ast

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

@en

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

@nl

P1433

Q28188441-7C239D52-D4D7-495A-AEB9-241755BBF99D

P1476

Q28188441-4E7CC6B8-4A0B-48A8-81F4-254F94A855CC

P2093

Q28188441-31E6CCAF-9B82-4F42-BEA2-DA66D97CC44A

Q28188441-37AAD3CE-220C-46B8-BDD0-18943644A46C

Q28188441-47E90190-FF88-4B1B-AED0-1AFA7C7610CA

Q28188441-9B376F3A-34C6-4BFC-B50B-C045E5DD40C6

Q28188441-A388D6E4-D2C6-4649-A2F5-663ECC6850AF

Q28188441-BA128321-84DC-4445-83AB-6BF362F5BDC8

Q28188441-BE15BDF9-C2E9-41AB-AF3E-5D795FB8CEF5

Q28188441-D67524E8-EA51-4A65-B0FC-930391E55DA8

Q28188441-DF12AF07-808B-4F02-974D-7E94E1736C11

P304

Q28188441-C644A832-B7CF-457E-9336-34670CC74032

P31

Q28188441-C535EC45-4A82-441A-84A0-9830038AEB4C

P3181

Q28188441-00CE833D-FA14-4038-A63E-C53C8FB1BD92

P356

Q28188441-AD67817F-F914-45E8-B824-71C96B957C4C

P407

Q28188441-5E7E8538-39AE-42EB-80D7-78BB2662F6C8

P433

Q28188441-10CD2820-A389-4420-91D6-23C467165F31

P478

Q28188441-37ABDBAB-9A99-4757-8895-913C9915325D

P577

Q28188441-506BFA85-E314-4FE5-9F43-DC398F62E777

P698

Q28188441-51A5286B-5353-4FE4-A95C-E7826B810CAD

P921

Q28188441-FBA6EDEA-0818-4447-9C3B-3460A61C006F

P3181

P356

NEJM199211193272102

P1433

The New England Journal of Medicine

P1476

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

@en

P2093

A Gottlieb

http://www.w3.org/2001/XMLSchema#string

B A Peterson

http://www.w3.org/2001/XMLSchema#string

E S Henderson

http://www.w3.org/2001/XMLSchema#string

G P Canellos

http://www.w3.org/2001/XMLSchema#string

J R Anderson

http://www.w3.org/2001/XMLSchema#string

K J Propert

http://www.w3.org/2001/XMLSchema#string

M R Cooper

http://www.w3.org/2001/XMLSchema#string

M R Green

http://www.w3.org/2001/XMLSchema#string

N Nissen

http://www.w3.org/2001/XMLSchema#string

P304

1478-84

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1456312

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJM199211193272102

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

327

http://www.w3.org/2001/XMLSchema#string

P577

1992-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

1383821

http://www.w3.org/2001/XMLSchema#string

P921